Unichem Laboratories Hit With ₹87.07 Crore CGST Penalty, Aims To Appeal

Market snapshot: Unichem Laboratories Limited has received an Order-in-Appeal from the Commissioner (Appeals), Thane on September 18, 2026, confirming a CGST penalty of ₹87.07 crore along with an interest liability of ₹6.59 crore. The pharmaceutical company has announced plans to challenge the order by filing an appeal within the prescribed timelines. Management maintains that this tax dispute, which relates to the cross-charge of common services, will have no material impact on its financial or operational activities.

Data Snapshot

• Adverse Order-in-Appeal received from the Commissioner (Appeals), Thane confirms a CGST penalty of ₹87.07 crore under Section 74(1) and Section 122(2)(b).
• Interest liability of ₹6.59 crore has been upheld for the delayed payment of tax liabilities.

What's Changed

• The Commissioner (Appeals), Thane has confirmed the penalty of ₹87.07 crore and interest of ₹6.59 crore, disallowing the appeal filed by the company against the assessment order originally received on January 24, 2025.

Key Takeaways

• The Commissioner (Appeals), Thane, has confirmed a CGST penalty of ₹87.07 crore under Sections 74(1) and 122(2)(b) of the CGST Act, 2017.
• An interest liability of ₹6.59 crore has also been confirmed due to delayed tax payments under Section 13 of the CGST Act, 2017.
• The underlying tax dispute relates to the cross-charge of common services.
• Unichem intends to challenge the appellate order by filing a further appeal within prescribed timelines, based on legal advice.
• Management expects no material impact on the financial, operational, or other business activities of the company.

SAHI Perspective

The confirmation of a ₹87.07 crore penalty plus ₹6.59 crore interest represents a notable regulatory hurdle for Unichem Laboratories. Although management has reassured the market that the dispute will have no material financial or operational impact, a total demand of ₹93.66 crore (derived: ₹87.07 crore penalty + ₹6.59 crore interest) is substantial compared to historical figures. Given that the company plans to pursue further legal remedies, investors should expect some near-term overhang regarding legal expenses and provisions. The core dispute around the cross-charge of common services highlights ongoing industry-wide friction between corporate entities and GST authorities regarding internal service valuations.

Market Implications

While Unichem Laboratories plans to contest the ruling and states there is no material impact on operations, the confirmation of a ₹93.66 crore total demand may create a temporary sentiment overhang on the stock. If legal proceedings drag on, it could require financial provisions or disclosures in upcoming quarterly reports. However, the company's solid net worth of ₹2,627.10 crore as of FY25-26 provides a robust cushion to handle potential contingencies without disrupting cash flows.

Trading Signals

Market Bias: Bearish

Near-term negative sentiment expected as the Commissioner (Appeals), Thane confirms a ₹87.07 crore penalty and ₹6.59 crore interest liability, totaling ₹93.66 crore. While the company intends to appeal further, the confirmed tax overhang could impact stock sentiment.

Underweight: Pharmaceuticals & Biotechnology

Trigger Factors:

• Filing of the formal appeal by the company and any stay order obtained on the penalty.
• Upcoming Q2 FY27 earnings disclosures regarding any provisions made for this tax liability.

Time Horizon: Near-term (0-3 months)

Industry Context

The pharmaceutical sector in India has frequently faced tax scrutiny regarding cross-charges—which involve transferring service costs between corporate headquarters and manufacturing units or subsidiaries. Since a substantial portion of Indian pharma companies operate global structures with multiple localized entities, transfer pricing and GST cross-charges remain active areas of regulatory litigation. The dispute here centered on Section 13 of the CGST Act, 2017, highlighting strict enforcement by GST authorities regarding tax supply timelines.

Key Risks to Watch

• Extended litigation timelines that prolong the financial uncertainty around the ₹93.66 crore demand.
• Auditors requiring explicit provisions in future earnings, directly impacting net profit margins.
• Potential of increased regulatory audits on cross-charges in other manufacturing facilities.

Recent Developments

Unichem Labs Receives Revised GST Order: The company received an order on July 28, 2026 from the Additional Commissioner, CGST (Appeals), Dehradun, partially allowing its appeal against an earlier order disallowing GSTR TRAN 1 credit of ₹73.03 lakh.

Closing Insight

While Unichem's operational engine remains intact, the confirmation of this ₹93.66 crore tax demand serves as a reminder of the complex tax compliance landscape for Indian pharmaceutical companies. The stock's performance will likely remain sensitive to legal updates regarding the filing and potential stay of this penalty.

High Performance Trading with SAHI.